About OncoSil Medical
OncoSil Medical is a company based in Sydney (Australia) founded in 2005. OncoSil Medical offers products and services including OncoSil™. OncoSil Medical operates in a competitive market with competitors including Sana Biotechnology, Janux Therapeutics, Carisma Therapeutics, GigaGen and Kronos Bio, among others.
- Headquarter Sydney, Australia
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oncosil Medical Ltd
-
Annual Revenue
$764.01 K (USD)126.62as on Jun 30, 2025
-
Net Profit
-$9.86 M (USD)-26.74as on Jun 30, 2025
-
EBITDA
-$10.07 M (USD)-18.7as on Jun 30, 2025
-
Latest Funding Round
$8.7 M (USD), Post-IPO
May 26, 2025
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OncoSil Medical
OncoSil Medical is a publicly listed company on the ASX with ticker symbol OSL in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OncoSil Medical
OncoSil Medical offers a comprehensive portfolio of products and services, including OncoSil™.
Delivers targeted radiation to pancreatic tumors with chemotherapy.
People of OncoSil Medical
Unlock access to complete
Funding Insights of OncoSil Medical
Investors in OncoSil Medical
OncoSil Medical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Regal Funds Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long/short investment strategy is followed by this hedge fund.
|
Locked | Locked | Locked |
Investor details for OncoSil Medical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OncoSil Medical
Investment portfolio details for OncoSil Medical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OncoSil Medical
Detailed financials for OncoSil Medical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncosil Medical Comparisons
Peer comparison for OncoSil Medical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OncoSil Medical
OncoSil Medical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Janux Therapeutics, Carisma Therapeutics, GigaGen and Kronos Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer treatment are developed to target solid tumors.
|
|
| Locked | Locked | Locked |
Chimeric antigen receptor macrophages are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Antibody-based drugs for primary myopathies are developed and targeted.
|
Detailed competitors of OncoSil Medical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncosil Medical
Complete news archive for OncoSil Medical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoSil Medical
OncoSil Medical was founded in 2005.
OncoSil Medical is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Annual revenue of OncoSil Medical is $764.01K as on Jun 30, 2025.
OncoSil Medical was founded in 2005 in Sydney, Australia, within the medical device sector focused on oncology. Operations center on the development of OncoSil, a brachytherapy implant that delivers beta radiation via phosphorous-32 microparticles to target cancer cell DNA in the pancreas. Proprietary diluents are used as carriers for precise implantation into affected tissues, supporting localized treatment approaches.
OncoSil Medical's top competitors include Janux Therapeutics, Kronos Bio and Sana Biotechnology.
OncoSil Medical offers OncoSil™.
Yes, OncoSil Medical is publicly traded on ASX under the ticker symbol OSL.
OncoSil Medical has 1 investor. Key investors include Regal Funds Management.
The ticker symbol of OncoSil Medical is OSL on ASX.